# HexemBio

> HexemBio is a New York- and Berkeley-based biotech building what it calls the first blood stem cell rejuvenation therapy. Its Synthetic Human Yolk Sac platform recreates the embryonic environment where blood stem cells first arise, temporarily placing a patient's own aged hematopoietic stem cells into that synthetic young niche before returning them by IV infusion - rather than gene-editing or chemically reprogramming the cells. The company launched publicly in April 2026 with a $10.4M seed round led by Draper Associates, holds an FDA Orphan Drug Designation for a bone-marrow-transplant program in blood cancers, and is targeting first-in-human trials in 2027.

- **Founded:** 2024
- **Headquarters:** New York, United States
- **Founders:** Gabriel Levesque Tremblay (CEO, Co-Founder), Samira Kiani (CTO, Co-Founder), Mo Ebrahimkhani (CSO, Co-Founder), Samet Yildirim (CBO, Co-Founder), Joshua Hislop (Head of AI, Co-Founder)
- **Team size:** ~11 employees
- **Products:** Synthetic Human Yolk Sac platform, Rejuvenated Stem Cell Therapy (lead program), AI discovery platform
- **Notable:** Closed a $10.4M seed round led by Draper Associates (April 2026), Received FDA Orphan Drug Designation for its lead program (July 2025), Completed FDA Pre-IND meeting (January 2026)

## Products & services

- **Synthetic Human Yolk Sac platform** — A recreated embryonic microenvironment - a 'synthetic young niche' - where blood stem cells first emerge in development. Patient cells are temporarily placed into this niche to rejuvenate them, rather than being gene-edited or chemically reprogrammed.
- **Rejuvenated Stem Cell Therapy (lead program)** — An autologous therapy that rejuvenates a patient's hematopoietic stem cells and returns them via standard IV infusion. Lead indication targets bone marrow transplant in blood cancers such as AML and ALL. Holds FDA Orphan Drug Designation.
- **AI discovery platform** — Computational platform led by Head of AI Joshua Hislop used to identify cell-rejuvenation mechanisms and therapeutic targets, tied to the company's synthetic developmental biology research.

## Achievements

- Closed a $10.4M seed round led by Draper Associates (April 2026)
- Received FDA Orphan Drug Designation for its lead program (July 2025)
- Completed FDA Pre-IND meeting (January 2026)
- Foundational research published in Nature (February 2024)
- Advisory board includes Robert S. Langer, MIT Institute Professor and Moderna co-founder

## Latest updates

- **2026-04** — Public launch and close of $10.4M seed round led by Draper Associates, with SOSV and Seraphim participating.
- **2026-01** — Completed FDA Pre-IND meeting for the lead blood stem cell rejuvenation program.
- **2025-07** — Received FDA Orphan Drug Designation for its lead bone-marrow-transplant program.
- **2024-02** — Foundational research underpinning the Synthetic Human Yolk Sac published in Nature.

## Links

- Website: https://hexemb.io
- LinkedIn: http://www.linkedin.com/company/hexembio
- Twitter/X: https://twitter.com/hexib
- YouTube: https://youtu.be/hTfmDBpl0Ik

---

Profile page: https://yespress.io/hexembio
Published by YesPress — https://yespress.io
Last updated: 2026-08-05